Volume 29, Issue 3
DOI: 10.24205/03276716.2020.952
CT-guided 125I seeds interstitial brachytherapy for vaginal metastases of cervical cancer after radiotherapy
Abstract
Objective: This retrospective research aims to evaluate the effectiveness and safety of computed tomography (CT)-guided I-125 seed interstitial brachytherapy for vaginal recurrent cervical cancer in patients with a history of pelvic radiotherapy.
Methods: Six patients with vaginal recurrent cervical carcinoma were involved in this research between July 2012 and January 2017. They were all treated with CT-guided I-125 seed interstitial implantation in Hebei General Hospital. Follow-up was carried out after the surgery to evaluate the therapeutic efficacy, including symptoms of the patient and the local control rate of the tumor. Complications were also summarized to evaluate the safety.
Results: In 6 patients, the efficacy evaluation was PR1 and SD5, the local control rate was 100% (6/6) at 1 month and 2 months after operation，and the efficacy evaluation was CR1ã€SD2 and PD2, the local control rate was 66.7% (4/6) at 4 months and 6 months after the operation. 6 patients had different degrees of vaginal discharge and bleeding decrease, and pain relief after the operation. 3 patients had 3, 4, and 8 seeds falling off within 10 days after surgery, and 1 patient developed hypothermia on the 2nd and 3rd day after surgery. No other serious adverse reactions were observed.
Conclusion: Reirradiation with CT-guided I-125 seed interstitial brachytherapy is a safe, effective, and minimally invasive method to treat patients with vaginal recurrent cervical cancer after radiotherapy.
Keywords
Cervical cancer; Vaginal recurrent; I-125 seeds; Brachytherapy